Effect of Antireflux Therapy on the Expression of Genes in Patients With GERD

• Status: Terminated
• Trial end date: 2014-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Although the symptomatic and epithelial (histologic and endoscopic) response to antireflux therapy are well known and extensively studied, little is known of the genetic events occurring in response to proton pump inhibitor therapy. Preliminary data from our laboratory has shown, for example, that COX-2 expression is not only elevated in patients with gastroesophageal reflux disease but also can be correlated with pathologic esophageal acid exposure on 24 hour pH monitoring. Similar studies have suggested that antireflux surgery may normalize COX-2 gene expression. In contrast studies following ablation of dysplastic Barrett's epithelium have shown persistence of genetic changes associated with altered cellular function, despite the return of the histologic appearance to normal. Several key mediators of inflammation, metaplasia (Barrett's) and neoplasia have now been well characterized and shown to be important factors in the pathogenesis of esophageal injury. It is likely that successful antireflux therapy returns altered expression of these mediators toward normal although this hypothesis remains largely unexplored. The aim of this study is to investigate gene expression of key mediators of the spectrum of esophageal mucosal injury and the response to antireflux therapy.

Hypothesis: Antireflux therapy (proton pump inhibitor and surgical fundoplication) normalizes the expression of genes known to be involved in the pathogenesis of inflammation (esophagitis), metaplasia (Barrett esophagus) and neoplasia (adenocarcinoma).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Rochester
• Collaborator: Takeda Pharmaceuticals North America, Inc.
• Treatments: Dexlansoprazole; Lansoprazole

Criteria

Inclusion Criteria:

For patients with GERD

• Patients referred for anti-reflux surgery

• On PPI therapy for at least 6 months

• Positive ambulatory pH monitoring (%time pH<4 > 4.7)

• Age greater than 18 years old.

• Both genders

For non-GERD controls

• Negative ambulatory pH monitoring OR

• Upper endoscopy performed for non-GERD symptoms.

• Age greater than 18 years old.

• Both genders

Exclusion Criteria:

• Prior foregut surgery

• Contra-indications for operation (poor clinical status, etc.)

• Contra-indications for endoscopy and biopsy (esophageal or gastric varices, therapeutic anticoagulation with Coumadin or Heparin, etc.)

• Unwillingness to participate in all of the follow-up studies

• Pregnancy

• Patients using medications that may interfere with PPIs pharmacokinetics (sucralfate, ketoconazole (Nizoral), ampicillin (Omnipen, Principen), digoxin (Lanoxin, Lanoxicaps), and iron (Feosol, Mol-Iron, Fergon, Femiron).

• Patients using medications that may interfere with gene expression (Immunosuppressants, Aspirin, NSAIDs, Corticosteroids).

• Patients with diseases that may interfere with gene expression (autoimmune diseases, diseases that course with immunosuppression).